Genedrive PLC - Interim Results for the six months to December 2017
- Genedrive's PLC (LON: GDR) HepC test just entered the commercial phase as partner Sysmex launched in EMEA and APAC territories in recent weeks
- Re-design of the mTB test in progress, launch date to be announced in the next fiscal year
- Discussions for the disposal of the Services business entered an exclusivity period, expect an update by the end of June
- Careful cash management with a £3.9mln cash balance at the end of February, we would expect a capital raise in the second half of calendar year 2018
Executive summary
As discussed more in depth in our initiation note of November 2017, we value Genedrive PLC on a SOTP basis.
Based on expected revenue of c. £15 mln in 2025, we value Genedrive’s diagnostic division approx. £24 mln.
Including the value we attribute to the Services business and the company's net debt leads to an equity valuation of about £24 mln, 3-4x current market capitalization.
Quick facts: Genedrive PLC
Price: 15.5 GBX
Market: AIM
Market Cap: £5.27 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERELEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...
FOR OUR FULL DISCLAIMER CLICK HERE
